Diamyd Medical AB (DMYDY.PK) said its third-quarter pre-tax loss narrowed to SEK 1.93 million from last year's SEK 43.61 million.
Loss reduced to SEK 1.93 million from SEK 43.45 million in the same quarter a year ago.
Group net sales amounted to SEK 348 thousand, significantly lower than SEK 19.53 million in the prior-year quarter.
Separately, Diamyd Medical revealed that a Phase II study evaluating the company's drug candidate NP2 Enkephalin did not meet its primary objective of reducing pain in subjects with severe intractable cancer pain. The treatment was however well tolerated, confirming the safety of the company's NTDDS technology.
The purpose of the randomized, double-blind, and placebo-controlled Phase II study is to evaluate the effect of intradermal injection of NP2 Enkephalin on pain reported by subjects suffering from severe intractable pain due to cancer, as well as to confirm the safety of the treatment.
Click here to receive FREE breaking news email alerts for Diamyd Medical and others in your portfolio
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org